Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT)
详细信息 查看全文
- 作者：Yvonne A. Efebera1 ; yvonne.efebera@osumc.edu" class="auth_mail" title="E-mail the corresponding author ; Susan Geyer1 ; 2 ; Leslie Andritsos1 ; Sumithira Vasu1 ; Samantha Jaglowski1 ; Anissa Bingman1 ; William Blum1 ; Rebecca Klisovic1 ; Craig C. Hofmeister1 ; Don M. Benson1 ; Sam Penza1 ; Patrick Elder1 ; Katie Cortright1 ; Rhonda Kitzler3 ; Kevin Coombes4 ; Lynn O'Donnell1 ; Beth Daneault1 ; Hillary Bradbury1 ; Jianying Zhang4 ; Xilin Chen1 ; Sabrina Garman1 ; Parvathi Ranganathan1 ; Xueyan Yu1 ; Jessica Hofstetter1 ; Jianhua Yu1 ; Ramiro Garzon1 ; Scott R. Scrape3 ; Gerard Lozanski3 ; Steven M. Devine1
- 关键词：Atorvastatin ; Allogeneic hematopoietic stem cell transplant ; Graft-versus-host-disease
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：22
- 期：1
- 页码：71-79
- 全文大小：1053 K
文摘
- •
Atorvastatin did not reduce incidence of grades 2-4 aGVHD in matched-related allo-HSCT
- •
Atorvastatin was well tolerated by both sibling donors and patients
- •
Atorvastatin affects Natural Killer and T-regulatory cells compared to control
- •
Atorvastatin did not affect cytokine expression compared to control